Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 1 3Phase EARLY_PHASE1 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1Dermatologic 1

Conditions

Pancreatic Neoplasms 2Prostatic Neoplasms 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 146pembrolizumab 120Magnetic Resonance Spectroscopy 117Cyclophosphamide 114Biopsy 97fludarabine 88Nivolumab 52Carboplatin 51Cisplatin 47Gemcitabine 46venetoclax 41Radiotherapy 41Paclitaxel 40Cetuximab 40fludarabine phosphate 39Ipilimumab 34atezolizumab 33Fluorouracil 33Bevacizumab 33Oxaliplatin 27Leucovorin 27Dexamethasone 27durvalumab 26X-Rays 25Irinotecan 25Radiation 24Cytarabine 24Azacitidine 24Injections 22Temozolomide 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Hydroxychloroquine × 90 days × Clear all
NCT03825289 2026-05-14

THREAD

University of Utah

Phase 1 Terminated
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT04132505 2026-04-06

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
34 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡